Clinical Trials Logo

Small Cell Lung Cancer Recurrent clinical trials

View clinical trials related to Small Cell Lung Cancer Recurrent.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03823118 Completed - Clinical trials for Small Cell Lung Cancer Recurrent

S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer

Start date: March 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of S1 combination with Anlotinib in patients with small cell lung cancer whose cancer has progression or recurrence after at least one standard chemotherapy.

NCT ID: NCT01441297 Completed - Clinical trials for Small Cell Lung Cancer

BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer

Start date: December 2011
Phase: Phase 2
Study type: Interventional

Although chemotherapy is the primary treatment option for small cell lung cancer (SCLC), longterm survival is rare. SCLC is initially chemosensitive, but rapidly relapses in a chemoresistant form with an overall survival of <5%. Consequently, novel therapies are urgently required and will likely arise from an improved understanding of the disease biology. Some preclinical studies have showed that fibroblast growth factor-2 induces proliferation and